Search Results - "UEOKA, H"

Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion by Murata, Y., Aoe, K., Mimura‐Kimura, Y., Murakami, T., Oishi, K., Matsumoto, T., Ueoka, H., Matsunaga, K., Yano, M., Mimura, Y.

“…Summary The cause of pleural effusion remains uncertain in approximately 15% of patients despite exhaustive evaluation. As recently described immunoglobulin…”
Get full text

Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials by Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Tanimoto, M.

“…Background: Single new agents reportedly produce promising response and survival effects, but platinum-based doublets remain the standard chemotherapy for…”
Get full text

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer by TAKIGAWA, N, KIURA, K, TABATA, M, SHINKAI, T, HIRAKI, S, TAKEMOTO, M, KANAZAWA, S, MATSUO, K, TANIMOTO, M, SEGAWA, Y, WATANABE, Y, KAMEI, H, MORITAKA, T, SHIBAYAMA, T, UEOKA, H, GEMBA, K, YONEI, T

“…Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who…”
Get full text

Phase I II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer by Kiura, K, Ueoka, H, Segawa, Y, Tabata, M, Kamei, H, Takigawa, N, Hiraki, S, Watanabe, Y, Bessho, A, Eguchi, K, Okimoto, N, Harita, S, Takemoto, M, Hiraki, Y, Harada, M, Tanimoto, M

“…Recent studies have suggested the superiority of concomitant over sequential administration of chemotherapy and radiotherapy. Docetaxel and cisplatin have…”
Get full text

Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer by KATAYAMA, H, UEOKA, H, SHIMIZU, N, TAKEMOTO, M, HIRAKI, Y, KIURA, K, TABATA, M, KOZUKI, T, TANIMOTO, M, FUJIWARA, T, TANAKA, N, DATE, H, AOE, M

“…The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by surgery in patients with…”
Get full text

Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience by Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Harita, S., Gemba, K., Yonei, T., Bessho, A., Tanimoto, M.

“…Background: This study aimed to investigate the survival outcome of patients with non-small-cell lung cancer (NSCLC) who had obtained disease stabilisation…”
Get full text

Evaluation of various cytological examinations by bronchoscopy in the diagnosis of peripheral lung cancer by KAWARAYA, M, GEMBA, K, UEOKA, H, NISHII, K, KIURA, K, KODANI, T, TABATA, M, SHIBAYAMA, T, KITAJIMA, T, TANIMOTO, M

“…To improve the efficacy of fibreoptic bronchoscopy in the diagnosis of peripheral lung cancer, we evaluated the effectiveness of various techniques for…”
Get full text

Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer by DATE, H, KIURA, K, UEOKA, H, TABATA, M, AOE, M, ANDOU, A, SHIBAYAMA, T, SHIMIZU, N

“…We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and irinotecan was feasible and could…”
Get full text

Treatment of unresectable non-small-cell lung cancer by Ueoka, H

“…Current progress in the treatment of unresectable non-small-cell lung cancer (NSCLC) is reviewed. Several new agents including vinorelbine, paclitaxel,…”
Get more information

Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group by UEOKA, H, TANIMOTO, M, KAMEI, H, SHIBAYAMA, T, WATANABE, Y, HIRAKI, S, HARADA, M, KIURA, K, TABATA, M, TAKIGAWA, N, SEGAWA, Y, TAKATA, I, EGUCHI, K, OKIMOTO, N, HARITA, S

“…A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted…”
Get full text

Treatment for brain metastases of lung cancer by Ueoka, H

“…Treatment for brain metastases of lung cancer was reviewed. For single brain metastasis of non-small cell lung cancer, surgical resection followed by whole…”
Get more information

A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group by SEGAWA, Y, UEOKA, H, HARADA, M, KIURA, K, KAMEI, H, TABATA, M, SAKAE, K, HIRAKI, Y, KAWAHARA, S, EGUCHI, K, HIRAKI, S

“…A recent meta-analysis and randomized studies have demonstrated that combined chemoradiotherapy is associated with a survival advantage for selected patients…”
Get full text

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study by UEOKA, H, TABATA, M, KIURA, K, SHIBAYAMA, T, GEMBA, K, SEGAWA, Y, CHIKAMORI, K, YONEI, T, HIRAKI, S, HARADA, M

“…A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however,…”
Get full text

Etoposide in the treatment of small-cell lung cancer by Ueoka, H

“…Etoposide is one of the most active agents for small-cell lung cancer. It is usually administered intravenously over 3 to 5 consecutive days in combination…”
Get more information

Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer by HOTTA, Katsuyuki, MATSUO, Keitaro, UEOKA, Hiroshi, KIURA, Katsuyuki, TABATA, Masahiro, TANIMOTO, Mitsune

“…It remains undetermined whether cisplatin and carboplatin are equally effective for advanced non-small-cell lung cancer (NSCLC). We therefore did a…”
Get full text

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY) by Hata, Tae, Ohashi, Kadoaki, Bessho, Akihiro, Hosokawa, Shinobu, Ishikawa, Nobuhisa, Yamasaki, Masahiro, Aoe, Keisuke, Kozuki, Toshiyuki, Harita, Shingo, Ueda, Yutaka, Murakami, Toshi, Fujimoto, Nobukazu, Yanai, Hiroyuki, Toyooka, Shinichi, Kiura, Katsuyuki, Gemba, K., Ikeda, G., Yasugi, M., Kurimoto, E., Nakano, K., Inoue, K., Miyoshi, S., Hamaguchi, N., Ito, R., Sano, Y., Takata, I., Mitani, A., Nishisaka, T., Nishida, A., Tamamoto, S., Fujitaka, K., Miyamoto, S., Hattori, N., Fujii, S., Sakugawa, M., Fukamatsu, N., Ogata, Y., Bandoh, S., Takigawa, N., Yamane, H., Honda, Y., Oka, M., Kittaka, M., Kubota, T., Yokoyama, A., Yokoyama, T., Sato, E., Shiota, Y., Kanematsu, T., Awaya, Y., Murakami, I., Kuyama, S., Kudo, K., Tamura, T., Umeno, T., Morichika, D., Sato, K., Harada, D., Nogami, N., Nishii, K., Fuchimoto, Y., Kawai, H., Watanabe, K., Tokumo, K., Isobe, T., Tsubata, Y., Inoue, M., Ichikawa, H., Nishioka, Y., Hanibuchi, M., Sumikawa, T., Kodani, M., Suyama, H., Makino, H., Shimizu, E., Obata, H., Ikegami, H., Chikamori, K., Maeda, T., Kamei, H., Ueoka, H., Kunihiro, Y., Kobayashi, T., Ueda, K., Hayashi, M., Murakami, J., Sato, A., Ichihara, E., Kubo, T., Ninomiya, T., Minami, D., Higo, H., Makimoto, G., Toyota, Y., Kayatani, H., Senoo, S., Kano, H., Watanabe, H., Itano, J., Tabata, M.

“…Human epidermal growth factor 2 (HER2) is a potential driver oncogene. Although HER2-targeted precision therapy has been tested in non-small cell lung cancer…”
Get full text

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : A pharmacogenetic analysis by ANDO, Yuichi, SAKA, Hideo, ANDO, Maki, SAWA, Toshiyuki, MURO, Kei, UEOKA, Hiroshi, YOKOYAMA, Akira, SAITOH, Soh, SHIMOKATA, Kaoru, HASEGAWA, Yoshinori

“…Irinotecan unexpectedly causes severe toxicity of leukopenia or diarrhea. Irinotecan is metabolized to form active SN-38, which is further conjugated and…”
Get full text

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers by TOKUMO, Masaki, TOYOOKA, Shinichi, TABATA, Masahiro, UEOKA, Hiroshi, TANIMOTO, Mitsune, DATE, Hiroshi, GAZDAR, Adi F, SHIMIZU, Nobuyoshi, KIURA, Katsuyuki, SHIGEMATSU, Hisayuki, TOMII, Kunitoshi, AOE, Motoi, ICHIMURA, Kouichi, TSUDA, Toshihide, YANO, Masaaki, TSUKUDA, Kazunori

“…Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor ( EGFR )…”
Get full text

Successful treatment with concurrent chemoradiotherapy followed by surgery for a patient with thymic adenocarcinoma by Shimono, M, Hiraki, A, Ueoka, H, Tanimoto, Y, Aoe, M, Sakae, K, Kaneda, K, Sakugawa, M, Kiura, K, Harada, M

“…Most neoplasms arising from the thymic epithelium are considered to be 'thymomas', which are composed of cytologically benign, neoplastic epithelial cells and…”
Get more information

Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis by Hiraki, A, Ono, T, Tanaka, M, Kiura, K, Ueoka, H, Kawai, H, Harada, M, Nakayama, E, Noguchi, Y

“…[corrected] Non-small cell lung cancer (NSCLC) is resistant to conventional treatment; so the development of a new therapy is urgent. 50 patients with NSCLC…”
Get more information